GlassScriptPhysician profile
Brandon Still
NPI 1215408604
$4,113.42
in general payments reported to CMS, 2019-2025
28 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $518 · 2022: $740 · 2023: $979 · 2024: $851 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,855.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $810.26 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $711.98 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $587.17 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $424.75 | 2021-2025 | |
| Lilly USA, LLC | $349.52 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $131.13 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.46 | 2024-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $117.69 | 2021-2023 | Xarelto |
| Amgen INC. | $106.88 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $87.28 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $72.42 | 2023-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.02 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $63.71 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $56.43 | 2024-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $55.86 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $45.96 | 2021-2023 | |
| Tolmar, INC. | $44.36 | 2023-2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $37.61 | 2023-2025 | Quviviq, Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $37.32 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $36.72 | 2021 | |
| Vivus LLC | $27.76 | 2022-2023 | Qsymia |
| Smith+Nephew, INC. | $24.83 | 2023 | Collagenase Santyl |
| Sumitomo Pharma America, INC. | $23.72 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $17.98 | 2022 | |
| Corcept Therapeutics | $15.91 | 2025 | Korlym |
| Verity Pharmaceuticals INC. | $15.45 | 2025 | Tlando |
| Supernus Pharmaceuticals, INC. | $13.66 | 2023 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Still listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.